China to make R&D for COVID-19 vaccine its top priority in next stage: Official

Outlining next st of country’s COVID-19 response, senior Chinese minister said that China will make research and development (R&D) of COVID-19 vaccine its top priority. China’s science and techlogy minister Wang Zhigan told a news conference that R&D for COVID-19 vaccines will mainly come from five technical routes including inactivated vaccine and evirus vector vaccine.

Wang also emphasised on accelerated development of antibody-drug in next phase with a focus on high success rate of entering into clinical trials and mass production. He also reiterated China’s commitment to make its COVID-19 vaccine a global public good once it is rey for application after successful research and clinical trials.

Potential vaccine

Last month, a Chinese pharmaceutical firm has reportedly verified safety of its potential vaccine after phase 2 clinical trials. According to a Chinese daily, Sivac Biotech Ltd has taken ar step towards trial production of vaccine, which is expected in July, and emergency use.

Sivac Biotech, first company in world to market H1N1 vaccine, is one of two COVID-19 inactivated-vaccine developers to have received approval for clinical trials in China. Last week, company published preclinical study on animals for its vaccine candidate against COVID-19.

In April, firm received approval to conduct phase I and phase II study on its inactivated vaccine candidate against COVID-19 in China. pharma company h commenced phase I trial and ministered drug on 144 healthy ults d 18-59 years.

Re: As China Threatens UK Of Breaking Business Commitments; US Comes To Ally's Rescue

Sivac CEO Weidong Yin said in a statement that vaccine candidate induced SARS-CoV-2-specific neutralizing antibodies in mice, rats, and n-human primates, specifically rhesus macaque. results showed that vaccine candidate offered safe and complete protection in rhesus macaques against SARS- CoV-2 strains, he ded.

“As we begin our phase I trials, we will also accelerate progress of our research in order to support worldwide fight against COVID-19. Sivac remains committed to developing vaccines for global use,” said Weidong.

Re: US Planning To Reopen Consulate In China's Wuhan By Late June Amid Rising Tensions

(Im credit: AP)